Skip to content

Validation of a Wireless Wearable Vital Signs Monitor in Pediatric Patient

Wireless Skin-Adherent Physiologic Sensor Validation in Pediatric Patients - Phase 1 Clinical Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07739823
Enrollment
42
Registered
2026-07-31
Start date
2026-09-01
Completion date
2027-09-01
Last updated
2026-07-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Physiologic Monitoring, Vital Signs Monitoring

Keywords

Wireless monitoring, Wearable sensors, Pediatric, Neonate, Infant, Intensive care, Physiologic monitoring

Brief summary

This prospective observational study aims to evaluate the accuracy, safety, and feasibility of the ANNE® Chest wireless wearable sensor for continuous monitoring of heart rate, respiratory rate, oxygen saturation, and skin temperature in hospitalized neonates, infants, and children (0 days to 12 years of age) in the neonatal and pediatric intensive care units (NICU and PICU). Measurements obtained from the wireless device will be compared with standard-of-care bedside monitoring and capnography. The study will also assess skin tolerability, signal reliability, and caregiver and healthcare provider perceptions of the device.

Interventions

DEVICEANNE® Chest Sensor

Participants will wear the ANNE® Chest wireless skin-adherent physiologic sensor for continuous monitoring of heart rate, respiratory rate, electrocardiography (ECG), skin temperature, and body position during the study period. Measurements obtained from the investigational device will be compared with simultaneous standard-of-care bedside monitoring and capnography for validation purposes.

Sponsors

McGill University Health Centre/Research Institute of the McGill University Health Centre
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
0 Days to 12 Years
Healthy volunteers
No

Inclusion criteria

* Neonates (0-28 days of life) * Infants (29 days of life - 2 years, i.e., not turned 2 years old) * Children (2 years old - 12 years old, i.e., not turned 12 years old)

Exclusion criteria

* Contraindication to application of skin sensors (e.g., rash, surgical site, skin breakdown, open wounds, burns, active dermatitis, etc.) at the application site. * Severe hemodynamic instability requiring escalating interventions. * Congenital airway abnormalities interfere with accurate capnography. * Diagnosed neuromuscular disorders affecting respiratory mechanics. * Known adhesive allergies. * Inability to tolerate device placement due to behavioral issues. * Participation in conflicting clinical trials. * High-frequency oscillatory or mechanical ventilation. * Active bronchiolitis with mask intolerance. * Recent facial surgery preventing EtCO₂ nasal line placement. * Behavioral conditions preventing adherence to device wearing.

Design outcomes

Primary

MeasureTime frameDescription
Respiratory Rate AccuracyStudy monitoring period (4 to 8 hours per day over 2 consecutive days)Agreement between respiratory rate measured by the ANNE® Chest wireless sensor and the reference standard capnography. Accuracy will be evaluated using agreement analyses, with success defined as wearable-derived respiratory rate values within ±3 breaths per minute of the reference standard.
Heart Rate AccuracyStudy monitoring period (4 to 8 hours per day over 2 consecutive days)Agreement between heart rate measured by the ANNE® Chest wireless sensor and the reference standard bedside monitor. Accuracy will be evaluated using agreement analyses, with success defined as wearable-derived heart rate values within ±5 beats per minute of the reference monitor.

Secondary

MeasureTime frameDescription
Skin TolerabilityBaseline (prior to device placement), immediately after device removal, and approximately 30 minutes after device removal.Skin tolerability of the ANNE® Chest sensor, including the presence of erythema, irritation, or pressure marks following device use. Skin integrity will be assess by comparing before and after photos of sites of placement of wearable sensors using the Berger \& Bowman Scoring Scale.
Caregiver and Healthcare Provider Device Usability PerspectiveImmediately following completion of study participation.Caregiver and healthcare provider feedback regarding the usability and acceptability of the ANNE®. Parent and clinician perceptions will be assessed using a custom study questionnaire containing Likert-scale, multiple-choice, and open-ended questions addressing usability, comfort, perceived safety, perceived accuracy, and overall acceptability of the wireless monitoring system.
Respiratory Rate Average Root Mean Squared Error (ARMS)Study monitoring period (4 to 8 hours per day over 2 consecutive days)Average Root Mean Squared Error (ARMS) between respiratory rate measurements obtained from the ANNE® Chest sensor and the reference monitor within each age cohort.

Contacts

CONTACTAlyssa Maximov, BSc.
alyssa.maximov@muhc.mcgill.ca5149341934
PRINCIPAL_INVESTIGATORGuilherme Sant'Anna, MD, PhD

RI-MUHC

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 1, 2026